Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Belviq
Belviq
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
Xconomy
Eisai
lorcaserin
Belviq
cancer
FDA
weight loss
Flag link:
FDA Warns of Potential Cancer Risk With Weight Loss Drug
FDA Warns of Potential Cancer Risk With Weight Loss Drug
RAPS.org
FDA
Belviq
Eisai
cancer
Flag link:
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
Forbes
obesity
Belviq
Flag link:
Eisai's weight-loss drug proves safe, but delivers no heart benefit
Eisai's weight-loss drug proves safe, but delivers no heart benefit
Biopharma Dive
Eisai
Belviq
New England Journal of Medicine
Flag link:
Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?
Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?
Fierce Pharma
Eisai
obesity
Belviq
Flag link:
Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday
Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Friday
Motley Fool
Arena Pharmaceuticals
ralinepag
Belviq
Flag link:
Arena Turns Page On Belviq - Restructures Deal With Eisai
Arena Turns Page On Belviq - Restructures Deal With Eisai
Seeking Alpha
Arena Pharmaceuticals
Belviq
Eisai
Flag link:
Drug maker faces a shareholder suit for failing to tell the whole truth
Drug maker faces a shareholder suit for failing to tell the whole truth
Stat/Pharmalot
shareholders
Arena Pharmaceuticals
Belviq
Flag link:
The Little-Known Reason Arena Pharmaceuticals Could Be a Winner
The Little-Known Reason Arena Pharmaceuticals Could Be a Winner
Motley Fool
Arena Pharmaceuticals
Belviq
CNS
Boehringer Ingelheim
Flag link:
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Seeking Alpha
Arena Pharmaceuticals
obesity
Orexigen
Belviq
Eisai
Vivus
Novo Nordisk
Qsymia
Victoza
Flag link:
Eisai slashes Belviq sales force as Arena marketing deal goes sour
Eisai slashes Belviq sales force as Arena marketing deal goes sour
Fierce Pharma Marketing
Eisai
layoffs
drug reps
Belviq
Arena Pharmaceuticals
Flag link:
Arena: Belviq Sales Still Slow - Will Eisai Stick Around?
Arena: Belviq Sales Still Slow - Will Eisai Stick Around?
Seeking Alpha
Arena Pharmaceuticals
Belviq
Eisai
obesity
Flag link:
Arena- Belviq Sales Slip In Second Week Of New Year
Arena- Belviq Sales Slip In Second Week Of New Year
Seeking Alpha
Arena Pharmaceuticals
Belviq
obesity
Flag link:
Belviq Sales Close Out 2015 With A Slump
Belviq Sales Close Out 2015 With A Slump
Seeking Alpha
Belviq
Arena Pharmaceuticals
obesity
Vivus
Orexigen
Flag link:
Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016?
Arena Pharmaceuticals Ends 2015 On a Sour Note: Can It Recover in 2016?
Motley Fool
Arena Pharmaceuticals
Belviq
Flag link:
Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
Yahoo
Eisai
Arena Pharmaceuticals
Belviq
FDA
Flag link:
Arena- Belviq Scripts See Small Rise But Still Lag Sector Where It Counts
Arena- Belviq Scripts See Small Rise But Still Lag Sector Where It Counts
Seeking Alpha
Arena Pharmaceuticals
Belviq
obesity
prescription data
Flag link:
Arena: Eisai Financials Offer Hints To Belviq Revenue In Q3
Arena: Eisai Financials Offer Hints To Belviq Revenue In Q3
Seeking Alpha
Arena Pharmaceuticals
Eisai
Belviq
Flag link:
Drug maker loses lawsuit filed to regain ‘lost’ marketing time
Drug maker loses lawsuit filed to regain ‘lost’ marketing time
Pharmalot
Eisai
Fycompa
Belviq
FDA
DEA
market exclusivity
Flag link:
No False Starts: FDA Prevails in Eisai Challenge Over NCE Exclusivity Start Dates for BELVIQ and FYCOMPA
No False Starts: FDA Prevails in Eisai Challenge Over NCE Exclusivity Start Dates for BELVIQ and FYCOMPA
FDA Law Blog
FDA
Eisai
exclusivity
Belviq
Fycompa
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »